+47.6%
GSK vs MKC
-31.2%
+78.8%
-28.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MKC | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.2% | -0.8% | +1.0% | +0.4% |
| 7D | -3.6% | -4.3% | +0.7% | -2.6% |
| 30D | -5.9% | -3.1% | -2.8% | -5.3% |
| 3M | -4.3% | +6.8% | -11.1% | -5.8% |
| 6M | -10.8% | -18.3% | +7.5% | -6.9% |
| YTD | +1.8% | -23.1% | +24.8% | +7.3% |
| 1Y | +23.5% | -23.7% | +47.2% | +30.3% |
| All | +47.6% | -31.2% | +78.8% | +57.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MKC.
Daily Out/Under-Performance
Portfolio return minus MKC return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MKC return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MKC wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling